source
- Quest Diagnostics reports cyberattack that may have exposed patient recordsQuest Diagnostics disclosed in an SEC filing that its Quanum LSM system was accessed without authorization on Oct 21, potentially compromising patient data. The breach affected a system used by ce…
- Rebranded Rezera plans IPO to fund phase 3 trial of NLRP3 inhibitor ruvonoflast for peripheral artery diseaseRezera, which rebranded from NodThera last month, announced plans for an initial public offering to raise capital for its lead candidate, ruvonoflast, a brain‑penetrant NLRP3 inhibitor. The compan…